NASDAQ:AERI

Aerie Pharmaceuticals Stock Forecast, Price & News

$12.27
+0.68 (+5.87 %)
(As of 09/21/2021 04:00 PM ET)
Add
Compare
Today's Range
$11.36
$12.55
50-Day Range
$11.59
$16.63
52-Week Range
$9.01
$21.30
Volume3.11 million shs
Average Volume600,349 shs
Market Capitalization$579.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72
30 days | 90 days | 365 days | Advanced Chart
Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Aerie Pharmaceuticals logo

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

299th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

38th out of 193 stocks

Analyst Opinion: 3.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

Is Aerie Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Aerie Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AERI, but not buy additional shares or sell existing shares.
View analyst ratings for Aerie Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Aerie Pharmaceuticals?

Wall Street analysts have given Aerie Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Aerie Pharmaceuticals
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Tuesday, August, 3rd. The company reported ($0.67) EPS for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.02. Aerie Pharmaceuticals had a negative trailing twelve-month return on equity of 1,531.00% and a negative net margin of 175.35%.
View Aerie Pharmaceuticals' earnings history
.

How has Aerie Pharmaceuticals' stock price been impacted by COVID-19?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AERI stock has decreased by 15.7% and is now trading at $12.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AERI?

5 analysts have issued 12 month price objectives for Aerie Pharmaceuticals' stock. Their forecasts range from $9.00 to $29.00. On average, they expect Aerie Pharmaceuticals' share price to reach $21.13 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Vicente J. Anido, Chairman & Chief Executive Officer
  • Thomas A. Mitro, President & Chief Operating Officer
  • Christopher Staten, Chief Financial Officer
  • Casey C. Kopczynski, Chief Scientific Officer
  • Richard Lewis, Chief Medical Officer

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Bank of America Corp DE (5.56%), William Blair Investment Management LLC (4.63%), Levin Capital Strategies L.P. (2.86%), Citigroup Inc. (2.65%) and Rice Hall James & Associates LLC (2.65%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski and Gerald D Cagle.
View institutional ownership trends for Aerie Pharmaceuticals
.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Woodline Partners LP, Rice Hall James & Associates LLC, Tri Locum Partners LP, Principal Financial Group Inc., Atika Capital Management LLC, Granite Investment Partners LLC, and Bank of America Corp DE.
View insider buying and selling activity for Aerie Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Integral Health Asset Management LLC, Levin Capital Strategies L.P., M&G Investment Management Ltd., State Street Corp, Renaissance Technologies LLC, Millennium Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Aerie Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $12.27.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals has a market capitalization of $579.56 million and generates $83.14 million in revenue each year. The company earns $-183,100,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

Aerie Pharmaceuticals employs 365 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Where are Aerie Pharmaceuticals' headquarters?

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at (919) 237-5300 or via email at [email protected].


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.